Department of Surgery, University of Cambridge, Cambridge, UK.
NHS Blood and Transplant, Watford, Hertfordshire, UK.
BMJ Open. 2019 Jan 17;9(1):e026166. doi: 10.1136/bmjopen-2018-026166.
Most potential kidney transplant donors in the UK are aged over 60 years, yet increasing donor age is associated with poorer graft survival and function. Urgent preimplantation kidney biopsy can identify chronic injury, and may aid selection of better 'quality' kidneys from this group. However, the impact of biopsy on transplant numbers remains unproven. The PreImplantation Trial of Histopathology In renal Allografts (PITHIA) study will assess whether the introduction of a national, 24 hours, digital histopathology service increases the number, and improves outcomes, of kidneys transplanted in the UK from older deceased donors.
PITHIA is an open, multicentre, stepped-wedge cluster randomised study, involving all UK adult kidney transplant centres. At 4-monthly intervals, a group of 4-5 randomly selected clusters (transplant centres) will be given access to remote, urgent, digital histopathology (total intervention period, 24 months). The trial has two primary end points: it is powered for an 11% increase in the proportion of primary kidney offers from deceased donors aged over 60 years that are transplanted, and a 6 mL/min increase in the estimated glomerular filtration rate of recipients at 12 months post-transplant. This would equate to an additional 120 kidney transplants performed in the UK annually. Trial outcome data will be collected centrally via the UK Transplant Registry held by NHS Blood and Transplant (NHSBT) and will be analysed using mixed effects models allowing for clustering within centres and adjusting for secular trends. An accompanying economic evaluation will estimate the cost-effectiveness of the service to the National Health Service.
The study has been given favourable ethical opinion by the Cambridge South Research Ethics Committee and is approved by the Health Research Authority. We will present our findings at key transplant meetings, publish results within 4 years of the trial commencing and support volunteers at renal patient groups to disseminate the trial outcome.
ISRCTN11708741; Pre-results.
在英国,大多数潜在的肾脏移植供体年龄都在 60 岁以上,但随着供体年龄的增加,移植物的存活率和功能会变差。在移植前进行紧急肾脏活检可以识别慢性损伤,并可能有助于从该人群中选择更好的“质量”肾脏。然而,活检对移植数量的影响仍未得到证实。肾脏同种异体移植组织病理学的植入前试验(PITHIA)研究将评估在英国,从年龄较大的已故供体中引入全国范围内 24 小时数字组织病理学服务是否会增加肾脏移植的数量并改善其结果。
PITHIA 是一项开放、多中心、分步楔形集群随机研究,涉及英国所有成人肾脏移植中心。每隔 4 个月,一组 4-5 个随机选择的集群(移植中心)将获得远程、紧急的数字组织病理学(总干预期为 24 个月)。该试验有两个主要终点:有能力使来自 60 岁以上已故供体的初级肾脏供体的比例增加 11%,以及使移植后 12 个月受体的估计肾小球滤过率增加 6mL/min。这将相当于英国每年额外进行 120 例肾脏移植。试验结果数据将通过英国国民保健制度血液和移植中心(NHSBT)持有的英国移植登记册进行集中收集,并使用混合效应模型进行分析,该模型允许在中心内进行聚类,并调整季节性趋势。一项伴随的经济评估将估算该服务对国民保健制度的成本效益。
该研究已得到剑桥南部研究伦理委员会的有利伦理意见,并得到了卫生保健管理局的批准。我们将在主要的移植会议上介绍我们的发现,在试验开始后 4 年内公布结果,并支持肾脏患者团体的志愿者传播试验结果。
ISRCTN85405259;预结果。